The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The Emergency Department as a Setting-Specific Opportunity for Population-Based Hepatitis C Screening: An Economic Evaluation
Liv Int. 2020 Apr 8. doi: 10.1111/liv.14458. Online ahead of print.
Andrew B Mendlowitz12, David Naimark3, William W L Wong4, Camelia Capraru5, Jordan J Feld5, Wanrudee Isaranuwatchai26, Murray Krahn17
Author information
1Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada.
2Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
3Department of Medicine, Sunnybrook Hospital, Toronto, ON, Canada.
4School of Pharmacy, University of Waterloo, Waterloo, ON, Canada.
5Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, ON, Canada.
6St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
7University Health Network - Toronto General Hospital, Toronto, ON, Canada.
Abstract
Background and aims: The World Health Organization's hepatitis C virus (HCV) elimination strategy recognizes the need for interventions that identify populations most affected by infection. The emergency department (ED) has been suggested as a setting for HCV screening. The study objective was to explore the health and economic impact of HCV screening in the ED setting.
Methods: We used a microsimulation model to conduct a cost-utility analysis evaluating two ED setting-specific strategies: no screening, and screening and subsequent treatment. Strategies were examined for two populations: (a) the general ED patient population; and (b) ED patients born between 1945 and 1975. The analysis was conducted from a healthcare payer perspective over a lifetime time horizon. A reference and high ED HCV seroprevalence measure were examined in the Canadian healthcare setting.US costs of chronic infection were used for a scenario analysis of screening in the US healthcare setting.
Results: For birth cohort screening, in comparison to no screening, one liver-related death was averted for every 760 and 123 persons screened for the reference and high seroprevalence measures. For general population screening, one liver-related death was averted for every 831 and 147 persons screened for the reference and high seroprevalence measures. In comparison to no screening, birth cohort screening was cost-effective at CAN$25,584/quality-adjusted life year (QALY) and US$42,615/QALY. General population screening was cost-effective at CAN$19,733/QALY and US$32,187/QALY.
Conclusions: ED screening may represent a cost-effective component of population-based strategies to eliminate HCV. Further studies are warranted to explore the feasibility and acceptability of this approach.